Skip to content

    Strides Pharma Science Q1 FY27 earnings call

    STAR
    Healthcare·31 Jul 2026
    Management Summary

    Strides Pharma Science Limited reported a steady Q1 FY27 with 13% YoY topline growth, driven by strong Ex-US performance. The company maintained healthy gross and EBITDA margins despite geopolitical and inflationary pressures, while also reducing net debt. Strategic focus remains on niche US domains and expanding Ex-US markets, with key product approvals and acquisitions expected in H2.

    Highlights

    5

    • Topline grew 13% year-on-year, supported by broad-based contributions across businesses.

    • Ex-US markets demonstrated strong momentum, delivering 17% year-on-year growth to ₹587.5 crores.

    • Gross margin expanded 60 basis points year-on-year to 60.9%, driving 14% growth in absolute gross margin to ₹770.2 crores.

    • EBITDA margin maintained at 18.2%, broadly in line with Q4 FY26, despite absorbing ₹13.1 crores in incremental costs.

    • Reported PAT was ₹165.5 crores, up 56.7% year-on-year, including a ₹74.2 crore gain from Pivot Path divestment.

    Concerns

    3

    • US business revenue of ₹628.2 million ($68 million) reflected stable performance despite increased competition.

    • Ex-US revenue of $63 million was impacted by supply chain disruptions and shipment delays, a sequential dip from $70 million in Q4 FY26.

    • Experienced delays in a few product approvals, which are expected to materialize over coming quarters.

    Key financials

    Single quarter

    08 metrics
    1. 01Total Revenue₹1,215.7 Cr+13%YoY
    2. 02Gross Margin60.9%
    3. 03EBITDA₹229.8 Cr+5.4%YoY
    4. 04EBITDA Margin18.2%
    5. 05Operational PAT₹123.1 Cr+8%YoY

    Reported results

    Q1 FY27 against Q1 FY26

    Revenue₹1,265 Cr+12.9%
    Operating profit₹228 Cr+4.6%
    Operating margin18.0%−1.5 pts
    Net profit₹165 Cr+55.7%
    Earnings per share₹17.02+57.6%

    Revenue moved −4.4% against Q4 FY26. Quarters are not comparable for companies whose sales are seasonal.

    Revenue and operating margin, last 6 quarters

    1. Q4'2518.3%
    2. Q1'2619.5%
    3. Q2'2618.9%
    4. Q3'2619.7%
    5. Q4'2618.1%
    6. Q1'2718.0%

    As filed with the exchanges, not as described on the call.

    Segment breakdown

    • US Business₹628.2 Cr51.7%
    • Ex-US Business₹587.5 Cr48.3%
    Donut· Share of Revenue

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Debt

    Net ₹1,424.6 crores · 1.5x EBITDA

    Cost 7.6%

    M&A

    Pivot Path (Captive Global Capability Centre)

    divestment · closed · Consideration ₹NaN (undisclosed)

    Guidance & targets

    12
    CategoryTargetPriority
    Revenue
    North America Business Revenue
    $375 million
    		High
    Revenue
    US Business Growth Acceleration
    Significantly accelerate efforts
    		High
    Revenue
    US Business Growth Trajectory
    Improve
    		High
    Revenue
    Ex-US Business Growth
    Grow faster than company average
    		High
    Margin
    Gross Margins
    58% to 60% range
    		High
    Margin
    Gross Margins
    58-60% range
    		High
    Product Launches
    Total Product Launches
    about 10 launches
    		High
    Product Launches
    High-Revenue Potential Launches
    majority are $10 million plus revenue potential
    		High
    Product Approvals
    First Nasal Spray Approval
    sometime in the second half (Q3, Q4)
    		Medium
    Product Pipeline
    New Nasal Programs
    5 to 6 more nasal programs
    		High
    M&A
    Sandoz Acquisition Closure
    sometime in Q2
    		Medium
    Debt
    Net Debt Position
    fairly neutral
    		Medium

    What to watch in Q2 FY27

    5

    US Business Growth Improvement

    H2 FY27
    CurrentStable performance in Q1 FY27 despite competition
    TargetImproved growth in H2 FY27

    Why it matters

    Key to achieving the FY28 $375M North America target and overall company growth.

    the growth trajectory in the US should improve over the course of the year, with H2 expected to be stronger, supported by new approvals, launches and portfolio optimization initiatives.

    Risks & concerns

    6
    RiskSeverity

    Geopolitical Situation and Volatility

    Ongoing conflict in the Middle East remains volatile, impacting the operating environment. — Management acknowledged

    medium

    Supply Chain Disruptions and Inflationary Pressures

    Elevated freight costs, longer transit times, and inflationary pressures across operating cost items, leading to ₹13.1 crores incremental costs in Q1. — Management acknowledged

    medium

    Increased Competition in US Market

    Increased competition in certain products launched over the last few quarters, affecting US revenue stability. — Management acknowledged

    medium

    Delays in Product Approvals

    Experienced delays in a few product approvals, which are expected to materialize over the coming quarters. — Management acknowledged

    medium

    Proposed US Tariffs on Generic Pharmaceuticals

    Proposed tariffs starting August 2028, with limited visibility on final implementation framework; company is monitoring developments. — Management acknowledged

    low

    Bangalore Plant USFDA Inspection Observations

    USFDA inspection resulted in observations; company has replied and expects a response by end August or September, with no anticipated impact on current supplies or US business growth. — Both acknowledged

    medium

    Q&A highlights

    8

    “the first 2 quarters will be very soft. And having said that, the bulk of the launches is going to come from the second half onwards. And if you really see the entire construct, there are 5 levers which we are working on the U.S. business.”

    Addresses a key investor concern about US market performance and provides strategic levers for future growth, confirming H2 will be stronger.

    asked by Pratik Kothari

    3 min read7 chapters

    Detailed Narrative

    01

    Q1 FY27 Performance Overview

    Strides Pharma Science Limited reported a steady start to FY27, with a 13% YoY growth in topline. Despite geopolitical volatility🌐 and supply chain disruption🌐s, the company maintained healthy gross margins at 60.9% (up 60 bps YoY) and improved PAT. Reported PAT grew 56.7% YoY to ₹165.5 crores, while operational PAT increased 8% YoY to ₹123.1 crores, reflecting the resilience of its diversified business model.

    02

    US Business Strategy and Performance

    The US business generated ₹628.2 crores ($68 million) in Q1 FY27, reflecting stable performance amidst increased competition. The company's US strategy prioritizes profitability and portfolio quality over growth at any cost. Management reiterated its aspiration to build a $375 million North America business by FY28, driven by 5 key levers including controlled substances, new channels, new partnerships, new launches, and OTC portfolio. H2 FY27 is expected to be stronger with new approvals and launches.

    03

    Ex-US Business Momentum

    The Ex-US business demonstrated strong momentum, growing 17% YoY to ₹587.5 crores ($63 million). This segment continues to be a significant growth driver, with strong performance across Europe, the UK, Nordics, Australia, and Africa. While Q1 saw some shipment delays due to supply chain issues, resulting in a sequential dip from $70 million in Q4 FY26, these are considered timing-related📎 and are expected to recover in coming quarters, with the underlying demand remaining healthy.

    04

    Profitability and Cost Management

    Gross margins expanded 60 basis points YoY to 60.9%, driving a 14% growth in absolute gross margin to ₹770.2 crores. EBITDA for the quarter was ₹229.8 crores, up 5.4% YoY, with an 18.2% margin. The company absorbed ₹13.1 crores in incremental operating and freight costs attributable to geopolitical disruption🌐s, demonstrating effective cost optimization and resilience in its operating model.

    05

    Debt Management and Credit Rating Upgrade

    Net debt was reduced by ₹11.9 crores during the quarter, bringing the closing net debt to ₹1,424.6 crores and improving the net debt-to-EBITDA ratio to 1.52x from 1.55x at the end of FY26. The weighted average cost of debt was reported at 7.6%. CARE Ratings upgraded the company's Long-Term Bank Facilities rating to CARE A+; Stable from CARE A; Positive, reflecting consistent financial results and improved financial health.

    06

    Product Pipeline and Approvals in Niche Domains

    The company launched two products in Q1 FY27, expanding its commercialized portfolio to 72 products. It continues to focus on niche domains like Nasal Sprays, Transdermal Patches, and Controlled Substances. Management expects approval for its first nasal spray in H2 FY27 (Q3/Q4) and plans 5-6 more nasal programs over the next 12-18 months, targeting 10 product launches by March 2027, mostly with $10M+ revenue potential.

    07

    Divestment of Pivot Path Stake

    Strides divested its majority stake in Pivot Path, its Captive Global Capability Centre, generating a gain of ₹74.2 crores, which contributed ₹53.4 crores (net of tax) to reported PAT. The divestment was valued at ₹125 crores for the GCC business, with Strides retaining a 20% stake. This strategic move is expected to contribute to the company's PAT in the coming years as the third-party business grows.

    This is an AI-generated summary of a publicly available earnings call transcript.